Skip to content
RDL Network logo
2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections — Robert Snoeck (2002) | RDL Network